Author

Hai Bin Yu

Professor of Medicinal Chemistry, School of Pharmaceutical Sciences, Zhengzhou University - Cited by 4,940 - Drug Design - Drug Discovery - Medicinal Chemistry - Chemical Biology - New Scaffold Generation

Biography

Dr. Hai Bin Yu is expertise in Cardio-vascualr Surgery. He currently working in Zhengzhou University in department of Cardio-vascular Surgery. His researches of interests are Cardiovascular Diseases, Cardiac Surgery
Title
Cited by
Year
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy
K Tang, Y Wu, Y Song, B Yu*Journal of Hematology & Oncology 14, 68, 2021202
118
2021
Natural products as LSD1 inhibitors for cancer therapy
Y Fang, C Yang, Z Yu, X Li, Q Mu*, G Liao*, B Yu*Acta Pharmaceutica Sinica B 11 (3), 621-631, 2021202
69
2021
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: synthesis and clinical application
S Wang, XH Yuan, SQ Wang, W Zhao, XB Chen, B Yu*European Journal of Medicinal Chemistry 214, 113218, 2021202
56
2021
Double-Edged Roles of Protein Tyrosine Phosphatase SHP2 in Cancer and Its Inhibitors in Clinical Trials
Y Song, M Zhao, H Zhang, B Yu*Pharmacology & Therapeutics 230, 107966, 2022202
46
2022
Targeting LSD1 for acute myeloid leukemia (AML) treatment
S Zhang, M Liu, Y Yao*, B Yu*, H Liu*Pharmacological Research 164, 105335, 2021202
41
2021
New drug approvals for 2020: Synthesis and clinical applications
S Yuan, YQ Luo, JH Zuo, H Liu, F Li, B Yu*European Journal of Medicinal Chemistry 215, 113284, 2021202
40
2021
HIF-1: structure, biology and natural modulators
C YANG, Z ZHONG, S WANG, C Teng VONG, B YU*, Y WANG*Chinese Journal of Natural Medicines 19 (7), 521-527, 2021202
30
2021
Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy
Y Song, S Wang, M Zhao, X Yang, B Yu*Journal of Medicinal Chemistry 65, 3066–3079, 2022202
27
2022
Discovery of Dosimertinib, a Highly Potent, Selective and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer
Y Meng#, B Yu#, H Huang, Y Peng, E Li, Y Yao, C Song, W Yu, K Zhu, ...Journal of Medicinal Chemistry 64 (2), 9–937, 2021202
25
2021
The First Chinese Oral Anti-COVID-19 Drug Azvudine Launched
B Yu, J Chang*The Innovation 3 (6), 100321, doi: 10.1016/j.xinn.2022.100321, 2022202
23
2022
Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors
S Yuan, B Wang, QQ Dai, XN Zhang, JY Zhang, JH Zuo, H Liu, Z Chen, ...Journal of Medicinal Chemistry 64 (19), 14895–14911, 2021202
22
2021
Inhibiting autophagy enhances sulforaphane-induced apoptosis via targeting NRF2 in esophageal squamous cell carcinoma
Z Lu, Y Ren, L Yang, A Jia, Y Hu, Y Zhao, W Zhao, B Yu, W Zhao, J Zhang, ...Acta Pharmaceutica Sinica B 11 (5), 1246-1260, 212
20
2021
Annual Review of LSD1/KDM1A Inhibitors in 2020
Annual Review of LSD1/KDM1A Inhibitors in DJ Fu, J Li*, B Yu*European Journal of Medicinal Chemistry 214, 113254, 212
20
2021
Annual Review of Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibitors in 2021
Y Song, H Zhang, X Yang, Y Shi, B Yu*European Journal of Medicinal Chemistry 228, 114042, 2022202
19
2022
Repurposing Antidepressants for Anticancer Drug Discovery
Y Song, X Yang, B Yu*Drug Discovery Today 25 (7), 1924-1935, 2022202
18
2022
Discovery of [1,2,4]triazolo[1,5-a]pyrimidines derivatives as potential anticancer agents
JL Huo#, S Wang#, XH Yuan, B Yu*, W Zhao*, HM Liu*European Journal of Medicinal Chemistry 211, 113108, 2021202
18
2021
A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors
Y Song, M Zhao, Y Wu, B Yu*, HM Liu*Acta Pharmaceutica Sinica B 11 (3), 750-762, 2021202
16
2021
Discovery of the Triazolo[1,5‑a]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance
S Wang, SQ Wang, QX Teng, ZN Lei, ZS Chen, XB Chen*, HM Liu*, B Yu*Journal of Medicinal Chemistry 64 (21), 16187–16204, 2021202
13
2021
Drug repurposing: An effective strategy to accelerate contemporary drug discovery
P Zhan*, B Yu*, L Ouyang*Drug Discovery Today 25 (7), 1785-1788, 2022202
13
2022
Cu(OTf)2-Catalyzed Intramolecular Radical Cascade Reactions for the Diversity-Oriented Synthesis of Quinoline-Annulated Polyheterocyclic Frameworks
S Yuan, J Zhang, D Zhang, D Wei, J Zuo, J Song, B Yu*, HM Liu*Organic Letters 23 (4), 1445–1450, 2021202
12
2021

Referred From: https://scholar.google.com/citations?user=qh6eZIMAAAAJ&hl=en

Cited by
Citations 4940
h-index 37
i10-index 98
Recommended Journals
Open Access Journals